Profound thrombocytopenia associated with tirofiban: Case report and review of literature

Angiology

Volumn 56, Issue 3, 2005, Pages 351-355

  Patel, Saumil ^a,b   Patel, Manali ^a,b   Din, Iftikhar ^a,b   Reddy, C V R ^a,b   Kassotis, John ^a,b  

^a New York Methodist Hospital ^*  (United States)

^b NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

AGED; CASE REPORT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

AGED; CORONARY DISEASE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; SYNDROME; THROMBOCYTOPENIA; TYROSINE;

EID: 18544377998     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600319     Document Type: Review

References (32)

1. Matthew W, McClure MW, Berkowitz SD: The Platelet Glycoprotein IIb/IIIa inhibitors in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience. Circulation 99:2892-2900, 1999.
2. Dasgupta H, Blankenship JC, Wood C: Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis. Am Heart J 140:206-211, 2000.
3. Package insert. Tirofiban (Aggrastat).
4. Package insert. Eptifibatide.
5. Package insert. Abciximab.
6. Berkowitz SD, Sane DC, Sigmon KN: Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for prevention of ischemic complication (EPIC) study group. J Am Coll Cardiol 32:311-319, 1998.
7. The IMPACT II Investigators: Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. IMPACT II. Lancet 349:1422-1428, 1997.
8. The CAPTURE Investigators: Randomized placebo-controlled trial of abcixirnab before and during coronary intervention in refractory unstable angina. The CAPTURE study. Lancet 349:1429-1435, 1997.
9. The EPILOG Investigators: Platelet glycoprotein IIb/ IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997.
10. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453, 1997.
11. The PRISM study investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. The platelet receptor inhibition in ischemic syndrome management. N Engl J Med 21:1498-1505, 1998.
12. The PRISM-PLUS study investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. N Engl J Med 21:1488-1497, 1998.
13. Theroux P, Kouz S, Roy L, et al: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 94:899-905, 1996.
14. Schulman SP, Goldschmidt-Clermont PJ, Topol FJ, et al: Effects of integrelin, a platelet glycoprotein IIb/ IIIa receptor antagonist, in unstable angina: A randomized multicenter trial. Circulation 94:2083-2089, 1996.
15. Theroux P, White H, David D, et al: A heparin-controlled study of MK-383 in unstable angina (abstract). Circulation 90(suppl):I-231, 1994.
16. Levadot J: A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb and Thrombol 9:175-180, 2000.
17. Glugliano RP, Hyatt RR Jr: Thrombocytopenia with GP IIb/IIIa receptor inhibitors: A meta-analysis (abstract). J Am Coll Cardiol 81:185, 1998.
18. Sane DC, Damaraju VV, Topol EJ: Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 36:75-83, 2000.
19. Payne BA, Pierre RV: Pseudothrombocytopenia: A laboratory artifact with potentially serious consequences. Mayo Clinic Proc 59:123-125, 1984.
20. Berkowitz SD, Harrington RA, Rund MM, et al: Acute profound thrombocytopenia associated with c7E3 Fab (abciximab). Circulation 95:809-813, 1997.
21. Hongo RH, Brent B: Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol 88:428-431, 2001.
22. Berkowitz SD, Granger CB: Thrombocytopenia was associated with greater hemorrhage and higher mortality in GUSTO lib trial. Thromb Haemost 236:PS-962, 1997.
23. Aster RH: Drug-induced immune thrombocytopenia: An overview of pathogenesis. Semin Hematol 36:2-6, 1999.
24. George JN: Drug induced thrombocytopenia. 2004 online journal, 3 pages. UpToDate.
25. George JN, Rizvi MA: Thrombocytopenia. In: Textbook of Hematology, chapter 117, ed. 6. Williams, 2001, pp 1495-1539.
26. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. Toward consensus. Thromb Haemost 79:1-7, 1998.
27. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292, 2001.
28. Warkentin TE: Heparin-induced thrombocytopenia. A clinicopathologic syndrome. Thromb Haemost 82:439-447, 1999.
29. Glugliano RP: Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors? J Thromb Thrombol 5:191-202, 1998.
30. The ReoPro Readministration Registry (R3): Safety of Abciximab retreatment. Final clinical report. J Am Coll Cardiol 33(suppl A):14-15, 1999.
31. Final report of an intravenous and oral GP IIb/IIIa inhibitor administered in patients. Results of TIMI 15B (abstract). Eu Heart J 20(suppl):876, 1999.
32. Naranjo CA, Busto U, Seller EM: A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 30:239-245, 1981.